This Monday, May 15th, representatives from bioXclusters plus and Fenglin Group signed a Gateway Agreement to offer free services and guidance for SMEs in their operations in China. Services will include assistance in market access, private investment, clinical trials and soft landing packages. Continue reading
The bioXclusters project partners are planning a trade mission to Shanghai (China) to learn mor about the life sciences sector in this country. The mission will take place from the 26th to the 31st May 2013 and plans to attend two events. All partners in the project as well as some companies located in the bioXcluster regions will take part in this mission. Continue reading
See this video about Mr. Gao Rohghui’s recent visit to Europe. It gives a great overview of what to do and what not to do when entering the Chinese life sciences market.
Click here to access this report about the Chinese biotech market published by the Nature Publishing Group. It contains information about the policies fostered by the different administrations, details joint ventures as an ideal formula for entering the market, informs of the role of the returnees and the strategy to attract talent,… (Dec. 2012)
There’s no question that China is an appealing market for the biotech industry. This is not only because of the possibilities it offers for lowering R&D costs, but also because of its market size. Demographics are a reason for this country’s attractiveness: a large and progressively wealthier population that is getting older represents a new market of potential users of biotech products.
But investing in China is not an easy process. The lack of transparency and the challenges related to regulatory issues make the process long and difficult, in addition to the maze of authorities involved. Continue reading